International Journal of Vaccine Theory, Practice, and Research 4(1)

https://doi.org/10.56098/hqjnk479

From Innovation to Inquiry — COVID -19 mRNA
Vaccination and Its Global Consequences —
with Special Reference to New Zealand
Bruce Rapley, PhD
Consultant and Independent Researcher, Smart Technology, New Zealand;

Abstract
The COVID-19 pandemic involved the rapid deployment of novel biomedical technologies. Chief
among them were synthetic RNAs, introduced with limited longitudinal data, yet supported by
institutional consensus, and expedited regulatory pathways. Subsequent developments revealed
questions regarding safety, ethics, efficacy, and governance. This formal review, with specific
reference to New Zealand, examines the COVID-19 response, using synthetic RNA distributed
under Emergency Use Authorizations. A range of post-deployment signals, including immunological
anomalies (IgG4 class switching), clotting disorders, and residual DNA elements, remain
insufficiently investigated. Regulatory responses have not met the standard of precaution typically
applied to novel gene therapies. At the same time, low-cost interventions such as ivermectin were de-
prioritized, or suppressed. The temporal association between vaccine rollouts and excess non-
COVID mortality in several high-uptake nations warrants systematic, transparent analysis. To date,
no national authority has published comprehensive disaggregated mortality data by vaccination
status.

Keywords: adverse events, COVID-19 vaccination, Emergency Use Authorization, EUA, genetic engineering, IgG4 class
switching, mRNA vaccination, plasmid DNA, post-market surveillance, therapeutic suppression, ivermectin, spike protein toxicity,
regulatory oversight failure, scientific censorship, turbo cancer, vaccine-induced thrombotic thrombocytopenia, VITT